GLP-1 Market
LLY $1251.61 ▲ +3.5% NVO $39.22 ▲ +2.9% PFE $29.44 ▲ +0.8% VKTX $27.37 ▲ +7.5% KLRA $11.71 ▲ +9.0% GPCR $22.19 ▲ +1.4% RHHBY $56.78 ▲ +2.0%
Market data delayed up to 20 min · Source: Twelve Data
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

BGM0504 administered subcutaneously ( ) once a week

BGM0504 administered subcutaneously ( ) once a week

Company
BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.
Mechanism
Mechanism not yet reported
Route
Injectable
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Oct 16, 2026

Trial details
  • Completed NCT NCT06704581

    A Study of BGM0504 Injection in Participants With Obesity or Overweight

    Not yet reported BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. 652 participants Est. completion 2026-03-17 1 site Stand-alone
    Other conditions: Overweight or Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: BGM0504 administered subcutaneously ( ) once a week, 10 mg BGM0504 injection administered subcutaneously (SC) once a week

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.